In this section:

04 September 2018

APRICOT Trial Protocol Published

The open access paper provides details of the study, which is testing a potential new treatment for Palmo-Plantar Pustulosis (PPP).

A new paper has just been published describing the protocol for the APRICOT trial. APRICOT, which stands for Anakinra for Pustular psoriasis: Response in a Controlled Trial, is a trial to test a potential new drug treatment (Anakinra) for Palmo-Plantar Pustulosis (PPP) - pustular psoriasis of the palms of the hands and/or soles of the feet.

The paper is open access, which means it is available to view free of charge and without any barriers. You can read it here.

About APRICOT


APRICOT trial logo (website news)APRICOT is a clinical trial based at Guy’s Hospital, London, led by Professor Catherine Smith at St John’s Institute of Dermatology. The trial is testing whether the medication Anakinra is effective at treating PPP.

Recent research has shown that PPP may be caused by an abnormal pathway in the body's immune system, involving a protein called interleukin-1 (IL-1). Anakinra specifically blocks this IL-1 pathway. Daily treatment (injections) with Anakinra may therefore prove to be an effective way of reducing PPP symptoms. Anakinra is already licensed for use in other inflammatory conditions (such as rheumatoid arthritis) and has a good safety profile.

APRICOT collaborators, including the Psoriasis Association, have been involved in the project from the beginning and will also be instrumental in influencing the direction of the trial as part of the trial management group.

APRICOT is sponsored by Guy’s and St Thomas’ NHS Foundation Trust and is funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership.

The APRICOT study has recently passed its 'half way recruitment target', however 32 new participants are still required to start as soon as possible. The trial is currently running at centres in Bradford, Bristol, Cambridge, Cardiff, Derby, Dudley, Dundee, Harlow, Lancaster, Liverpool, London, Newcastle, Norwich, Poole, and Salford. New centres in Chelmsford, Exeter, Fife, Glasgow, Nottingham and Sheffield are also due to open very soon.

If you have PPP and would like to take part in the study, you can register your interest here.

The Psoriasis Association is the UK's leading national charity and membership organisation for people affected by psoriasis – patients, families, carers and health professionals Read More >

Get in touch

The Psoriasis Association Dick Coles House 2 Queensbridge Northampton NN4 7BF

Email: mail@psoriasis-association.org.uk

Tel :
01604 251 620
Fax :
01604 251 621
Registered with Fundraising Regulator -

© The Psoriasis Association Registered Charity: 257414 Scotland: SC039886 Privacy PolicyCookies

Site by Spoken Image | glitterfish

We use cookies to help us provide you with a better service, but do not track anything that can be used to personally identify you.

If you prefer us not to set these cookies, please visit our Cookie Settings page or continue browsing our site to accept them.